Synbiotics Interventions for Managing Cirrhosis and Its Complications
Status:
Completed
Trial end date:
2022-10-24
Target enrollment:
Participant gender:
Summary
Background Liver cirrhosis is commonly accompanied by intestinal dysbiosis and metabolic
defects. Many clinical trials have shown microbiota-targeting strategies represent promising
interventions for managing cirrhosis and its complications. However, the influences of the
intestinal metagenomes and metabolic profiles of patients have not been fully elucidated.
Methods administered lactulose, Clostridium butyricum, and Bifidobacterium longum infantis as
a synbiotic and used shotgun metagenomics and non-targeted metabolomics to characterize the
results.